enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC

enGene Therapeutics Inc.

2024-Q2 EPS reported $0.82

Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).
Cash and equivalents $264.8M; expects to fund operations into 2027.
Interim LEGEND cohort data (BCG-unresponsive ~20 patients) expected by end of Sep 2024; BLA mid-2026.
Plans to expand LEGEND with third cohort (70-100 patients) for papillary-only NMIBC, enrollment Q4 2024.
Deprioritized cystic fibrosis program EG-i08; Paul Hastings and Wouter Joustra elected to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.